Ascendis Pharma ADR (ASND) Stock Price, Quote & News

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clini...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 22 22 44

Website: ascendispharma.com

Address:

Tuborg Boulevard 12, Hellerup, Denmark

SenefAS Aug. 18 at 7:53 PM

I really like Ascendis and the last earnings are very good… It’s big candidate for a buyout $ASND $XBI

0 · Reply

JamesTaulman Aug. 18 at 2:44 AM

MON 8/17: $ASND – Remains Below the Round-$250 and the Nearby 50 DMA – Not Good 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-8-17-asnd-remains-below-the-round-250-and-the-nearby-50-dma-not-good/

0 · Reply

Tjcmd Aug. 16 at 3:28 PM

$ASND fyi

0 · Reply

JamesTaulman Aug. 15 at 2:26 AM

FRI 8/14: $ASND – Dipped to Our Noted Support of $240 – Rallied Into the Close – Needs to Reclaim Its 10 DMA at $249.79 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-8-14-asnd-dipped-to-our-noted-support-of-240-rallied-into-the-close-needs-to-reclaim-its-10-dma-at-249-79/

0 · Reply

JamesTaulman Aug. 14 at 2:53 AM

THU 8/13: $ASND – Continued Weakness – Triggered a 3rd Sell Signal @ $245.79 -2.1% 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-8-13-asnd-continued-weakness-triggered-a-3rd-sell-signal-245-79-2-1/

0 · Reply

JamesTaulman Aug. 13 at 2:25 PM

THU 8/13: $ASND – CALLING A 3RD SELL SIGNAL @ $245.79 -2.1% 10:07 AM – Calling a 3RD and FINAL SELL SIGNAL this morning as shares have once again fallen below the 10 DMA and are now beginning to break below the 50 DMA as well. With short-term support failing again and a more significant intermediate-term support level now under pressure, the technical deterioration warrants fully closing out this selection. ULTRA Trader’s Tip: Multiple Support Breaks Confirm the Trend • Repeated failures at the 10 DMA show that short-term momentum remains weak. • A developing break below the 50 DMA adds another significant technical violation. • When multiple support levels begin failing together, the evidence is telling you the trend is deteriorating—respect it. https://buyingbreakouts.com/thu-8-13-asnd-calling-a-3rd-sell-signal-245-79-2-1/

0 · Reply

Pika_Capital Aug. 13 at 1:30 PM

$ASND amazing quarter. Yorvipath is at $1B annualized rev run rate

1 · Reply

StocktwitsEarnings Aug. 13 at 12:03 PM

$ASND Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $3.22 up 603.12% YoY • Reported revenue of $339.29M up 114.68% YoY

0 · Reply

Estimize Aug. 13 at 10:03 AM

$ASND reported - EPS and - revenue for Q2. http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_content=ASND&utm_medium=

0 · Reply

JamesTaulman Aug. 13 at 3:14 AM

WED 8/12: $ASND – Continued Range-Bound Trading Ahead of Earnings in the Morning 10:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-8-12-asnd-continued-range-bound-trading-ahead-of-earnings-in-the-morning/

0 · Reply

BMO starts Ascendis at Outperform on further platform growth

2026-08-18T20:25:41.000Z - 16 hours ago

Ascendis Pharma initiated with an Outperform at BMO Capital

Aug 18, 2026, 8:00 AM EDT - 1 day ago

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

2026-08-17T07:57:50.000Z - 2 days ago

Ascendis Pharma reports Q2 EPS 90c, consensus 77c

2026-08-16T13:54:11.000Z - 2 days ago

Ascendis Pharma price target lowered to $329 from $345 at Barclays

2026-08-16T13:33:49.000Z - 2 days ago

Ascendis Pharma price target raised to $341 from $325 at TD Cowen

2026-08-16T13:16:23.000Z - 2 days ago

Ascendis Pharma price target raised to $290 from $280 at RBC Capital

Aug 13, 2026, 8:00 AM EDT - 6 days ago

Ascendis Pharma Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 6 days ago

Ascendis Pharma Earnings release: Q2 2026

Aug 13, 2026, 7:30 AM EDT - 6 days ago

Ascendis Pharma Reports Second Quarter 2026 Financial Results

Aug 6, 2026, 4:01 PM EDT - 12 days ago

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Ascendis Pharma Slides: Study update presentation

2026-07-23T12:55:55.000Z - 26 days ago

Ascendis Pharma price target raised to $275 from $256 at Morgan Stanley

Jul 8, 2026, 7:00 AM EDT - 6 weeks ago

Ascendis Pharma Slides: Study result presentation

2026-07-07T11:30:43.000Z - 6 weeks ago

Ascendis Pharma price target raised to $280 from $275 at RBC Capital

Jul 1, 2026, 12:10 PM EDT - 6 weeks ago

14 value stocks of companies primed for rapid growth through 2028

BILL BX CG FIGR GWRE HUBS KKR

2026-06-30T13:15:35.000Z - 7 weeks ago

Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial

Jun 30, 2026, 8:30 AM EDT - 7 weeks ago

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

2026-06-26T20:25:11.000Z - 7 weeks ago

Ascendis Pharma added to multiple Russell U.S. Indexes

Jun 26, 2026, 4:01 PM EDT - 7 weeks ago

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Jun 25, 2026, 4:01 PM EDT - 7 weeks ago

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

2026-06-14T20:40:05.000Z - 2 months ago

Ascendis Pharma completes Phase 3 PaTHway Trial

Jun 13, 2026, 4:00 PM EDT - 2 months ago

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Jun 13, 2026, 7:00 AM EDT - 2 months ago

Ascendis Pharma Slides: Study result presentation

2026-06-11T20:14:58.000Z - 2 months ago

Ascendis Pharma announces five-year data from PaTH Forward Trial

Jun 11, 2026, 4:01 PM EDT - 2 months ago

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Jun 11, 2026, 7:00 AM EDT - 2 months ago

Ascendis Pharma Slides: Study result presentation

2026-06-09T11:42:07.000Z - 2 months ago

Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer

BMRN

Jun 8, 2026, 4:59 PM EDT - 2 months ago

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

2026-05-18T20:26:36.000Z - 3 months ago

Ascendis Pharma initiated with a Buy at Citi

2026-05-15T12:41:33.000Z - 3 months ago

Ascendis Pharma price target raised to $329 from $324 at Evercore ISI

2026-05-11T09:20:44.000Z - 3 months ago

Ascendis Pharma price target raised to $345 from $342 at Barclays

2026-05-08T10:34:05.000Z - 3 months ago

Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo

2026-05-07T19:27:17.000Z - 3 months ago

Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)

May 7, 2026, 8:00 AM EDT - 3 months ago

Ascendis Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Ascendis Pharma Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

Ascendis Pharma Reports First Quarter 2026 Financial Results

May 6, 2026, 4:01 PM EDT - 3 months ago

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

May 2, 2026, 7:00 AM EDT - 3 months ago

Ascendis Pharma Slides: Study result presentation

Apr 30, 2026, 4:01 PM EDT - 3 months ago

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

Apr 21, 2026, 4:31 PM EDT - 4 months ago

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Apr 8, 2026, 12:00 PM EDT - 4 months ago

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Apr 8, 2026, 8:01 AM EDT - 4 months ago

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Ascendis Pharma Slides: Study update presentation

Apr 6, 2026, 4:01 PM EDT - 4 months ago

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

Mar 17, 2026, 8:30 AM EDT - 5 months ago

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

Mar 16, 2026, 8:00 AM EDT - 5 months ago

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Ascendis Pharma Slides: Study result presentation

Mar 2, 2026, 11:10 AM EST - 6 months ago

Ascendis Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:43 AM EST - 6 months ago

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 6 months ago

Ascendis Pharma Transcript: FDA announcement

Mar 2, 2026, 8:00 AM EST - 6 months ago

Ascendis Pharma Press release: FDA announcement

Mar 2, 2026, 8:00 AM EST - 6 months ago

Ascendis Pharma Slides: FDA announcement

Feb 27, 2026, 6:04 PM EST - 6 months ago

Ascendis wins U.S. approval for therapy for children with dwarfism

Feb 27, 2026, 5:57 PM EST - 6 months ago

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

Feb 11, 2026, 4:30 PM EST - 6 months ago

Ascendis Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Ascendis Pharma Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Ascendis Pharma Earnings release: Q4 2025

Feb 11, 2026, 4:01 PM EST - 6 months ago

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 4:01 PM EST - 6 months ago

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

Jan 12, 2026, 10:30 AM EST - 7 months ago

Ascendis Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 7 months ago

Ascendis Pharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 6:01 PM EST - 7 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:30 PM EST - 7 months ago

Ascendis Pharma Transcript: Study Update

Jan 8, 2026, 4:30 PM EST - 7 months ago

Ascendis Pharma Press release: Study Update

Jan 8, 2026, 4:30 PM EST - 7 months ago

Ascendis Pharma Slides: Study Update

Jan 8, 2026, 4:01 PM EST - 7 months ago

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

Jan 5, 2026, 8:30 AM EST - 8 months ago

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 10:37 AM EST - 8 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY INSM MASI NTRA PODD UNH WGS

Dec 8, 2025, 1:54 PM EST - 9 months ago

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

IYC MPWR GPIQ

Nov 25, 2025, 6:21 PM EST - 9 months ago

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Nov 25, 2025, 6:15 PM EST - 9 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Nov 17, 2025, 4:01 PM EST - 9 months ago

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Nov 12, 2025, 4:30 PM EST - 9 months ago

Ascendis Pharma Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Ascendis Pharma Earnings release: Q3 2025

Nov 12, 2025, 4:01 PM EST - 9 months ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 8:30 AM EST - 10 months ago

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Nov 5, 2025, 4:01 PM EST - 10 months ago

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

Nov 3, 2025, 4:01 PM EST - 10 months ago

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Nov 3, 2025, 9:58 AM EST - 10 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 8, 2025, 4:01 PM EDT - 11 months ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:01 PM EDT - 1 year ago

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Aug 28, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings release: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 28, 2025, 7:00 AM EDT - 1 year ago

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Jul 14, 2025, 4:01 PM EDT - 1 year ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Jul 12, 2025, 7:00 AM EDT - 1 year ago

Ascendis Pharma Slides: Study result presentation

Jul 7, 2025, 4:01 PM EDT - 1 year ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Transcript: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Press release: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Slides: Study Update

Jun 9, 2025, 7:00 AM EDT - 1 year ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Jun 2, 2025, 8:00 AM EDT - 1 year ago

FDA Accepts TransCon® CNP NDA for Priority Review

May 20, 2025, 6:00 AM EDT - 1 year ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

SenefAS Aug. 18 at 7:53 PM

I really like Ascendis and the last earnings are very good… It’s big candidate for a buyout $ASND $XBI

0 · Reply

JamesTaulman Aug. 18 at 2:44 AM

0 · Reply

Tjcmd Aug. 16 at 3:28 PM

$ASND fyi

0 · Reply

JamesTaulman Aug. 15 at 2:26 AM

0 · Reply

JamesTaulman Aug. 14 at 2:53 AM

0 · Reply

JamesTaulman Aug. 13 at 2:25 PM

0 · Reply

Pika_Capital Aug. 13 at 1:30 PM

$ASND amazing quarter. Yorvipath is at $1B annualized rev run rate

1 · Reply

StocktwitsEarnings Aug. 13 at 12:03 PM

$ASND Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $3.22 up 603.12% YoY • Reported revenue of $339.29M up 114.68% YoY

0 · Reply

Estimize Aug. 13 at 10:03 AM

$ASND reported - EPS and - revenue for Q2. http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_content=ASND&utm_medium=

0 · Reply

JamesTaulman Aug. 13 at 3:14 AM

0 · Reply

Synaptric Aug. 12 at 7:55 PM

Renewed enthusiasm for space, drones, and AI energy are evident in the top three bullish names , $LUNR , $ONDS , $FRMI . Note the steep ascent in Fermi (tagged as a utility but clearly moving as an AI infrastructure play). The most bearish $BLSH began the period Bullish but fell early into Bearish and then stayed there. All but one ($ASND ) are sloped up for the day. None are in the Extremely Bearish zone.

1 · Reply

27R Aug. 12 at 3:50 PM

$ASND Buckle up — earnings before the open tomorrow.

0 · Reply

JamesTaulman Aug. 12 at 3:25 AM

TUE 8/11: $ASND – A Break Above the Round-$260 Would Be a Bullish Sign 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-8-11-asnd-a-break-above-the-round-260-would-be-a-bullish-sign/

0 · Reply

Doozio Aug. 12 at 12:28 AM

Can $BWAY continue to $ASND thru da $$$$ wen they all report eps ONTO 🐒🍌🧠⏰♾️

0 · Reply

JamesTaulman Aug. 11 at 2:42 AM

MON 8/10: $ASND – Remains Above Support Of The Stacked 10 DMA And The Round-$250 8:10 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-8-10-asnd-remains-above-support-of-the-stacked-10-dma-and-the-round-250/

0 · Reply

JamesTaulman Aug. 8 at 3:06 AM

FRI 8/7: $ASND – Did Clearly Clear Its 10 DMA – Now Needs to Break Out of Its 5-Week Downtrend 7:10 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-8-7-asnd-did-clearly-clear-its-10-dma-now-needs-to-break-out-of-its-5-week-downtrend/

0 · Reply

JamesTaulman Aug. 7 at 3:35 AM

THU 8/6: $ASND – Needs To More Convincingly Close Above The 10 DMA At $249.08 10:10 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-8-6-asnd-needs-to-more-convincingly-close-above-the-10-dma-at-249-08/

0 · Reply

27R Aug. 6 at 5:27 PM

$ASND Buckle up — earnings after the close today.

0 · Reply

CaptainAmrica Aug. 6 at 2:01 PM

$ASND $VRTX . That worked

0 · Reply

CaptainAmrica Aug. 5 at 1:40 PM

$ASND $VRTX . Yes sir.

0 · Reply

CaptainAmrica Aug. 4 at 7:48 PM

Need some bio.... $ASND $VRTX Starter....

1 · Reply

JamesTaulman Aug. 3 at 2:28 PM

MON 8/3: $ASND – CALLING A 2ND SELL SIGNAL @ $240.85 -4.0% 9:37 AM – Calling a 2ND SELL SIGNAL this morning (correction: the earlier email incorrectly stated a 1st SELL SIGNAL) as shares are clearly breaking below the 50 DMA. This loss of a major support level represents a meaningful technical violation and warrants further reducing the position. ULTRA Trader’s Tip: Major Support Levels Matter • The 50 DMA often serves as an important line of institutional support. • When a stock decisively breaks below that level, the probability of continued weakness increases. • Respecting major technical violations early helps preserve capital and keeps small losses from becoming much larger ones. https://buyingbreakouts.com/mon-8-3-asnd-calling-a-2nd-sell-signal-240-85-4-0/

0 · Reply

Market Cap	15.43B
Revenue (ttm)	814.76M
Net Income (ttm)	-258.00M
EPS (ttm)	N/A
PE Ratio	138.06
Forward PE	55.35
Profit Margin	-31.67%
Debt to Equity Ratio	0.31

Volume	452,600
Avg Vol	706,560
Day's Range	N/A - N/A
Shares Out	62.38M
Stochastic %K	46%
Beta	0.39
Analysts	Strong Sell
Price Target	$308.78